Method for synthesizing adenosine and / or uridine through three-enzyme cascade catalysis
Through the three-enzyme cascade catalytic method, the combination of ribokinase, pentose phosphate mutase and nucleoside phosphate enzymes is solved, and the problem of long and poor environmental protection of adenosine and uridine synthesis in the prior art is achieved, thus achieving high efficiency , environmentally friendly synthesis of adenosine and uridine reduces production costs.
Patent Information
- Application Number
- CN202310516643.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-09
- Publication Date
- 2024-11-12
AI Technical Summary
In the prior art, the synthesis method of adenosine and uridine has problems such as long steps, harsh reaction conditions, high environmental pollution and high cost, especially the low efficiency and poor environmental protection of chemical synthesis and biological fermentation methods.
Using the three-enzyme cascade catalytic method, specific enzyme combinations are designed to achieve efficient synthesis of adenosine and uridine, including ribokinase (RK), through the combination of ribokinase, pentose phosphate mutase and nucleoside phosphate enzymes. A combination of pentose phosphate mutaase (PPM) and nucleoside phosphate (NP), enzymes from different sources are engineered to improve synthesis efficiency.
It realizes efficient synthesis of adenosine and uridine, improves yield and environmental protection, reduces production costs, and provides a more efficient and environmentally friendly biotechnology route.
Smart Images

Figure CN118931997A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology and relates to a method for synthesizing adenosine and / or uridine by three-enzyme cascade catalysis. Background Art
[0002] Adenosine is a naturally occurring endogenous purine nucleoside found throughout human cells and is a degradation product of adenosine triphosphate (ATP). Adenosine is well known for its vasodilatory effect. In addition to its wide range of cardiac effects and rapid and significant coronary dilation, it also has cardioprotective effects such as triggering or mediating ischemic preconditioning and reducing reperfusion injury. Uridine is a pyrimidine nucleoside necessary for RNA and DNA synthesis. It has multiple biological functions and can play a role in the metabolism of sugars, fats, proteins and other substances by converting into intermediate bioactive molecules such as uridine diphosphate glucose and uridine diphosphate NK-acetylglucosamine.
[0003] The synthesis of adenosine and uridine can be divided into chemical synthesis, biological fermentation and enzyme engineering synthesis. For example, patent CN105884846A discloses a method for synthesizing 2'-deoxyadenosine, in which adenosine is subjected to esterification, acylation with an acylating agent and an acid-binding agent to obtain an acylate, and then the obtained acylate is subjected to reduction and purification to obtain 2'-deoxyadenosine, and the final HPLC purity can reach more than 99%. However, the preparation of 2'-deoxyadenosine by chemical synthesis has long steps and harsh reaction conditions, resulting in a low final yield, and various organic reagents are also required in the reaction process, which causes obvious environmental pollution; CN101575630A discloses a method for producing deoxyadenosine by bioconversion, which uses Lactobacillus helveticus as an enzyme source to catalyze the synthesis of 2'-deoxyadenosine; CN104178541A also discloses a method for producing 2'-deoxyadenosine by conversion using Escherichia coli, which directly uses Escherichia coli cells with high nucleoside phosphorylase activity as an enzyme source, and mixes them with deoxythymidine and adenine as conversion reaction substrates to carry out conversion reaction to synthesize 2'-deoxyadenosine, but the microbial fermentation process is relatively complex, costly, and has a long cycle, and the production efficiency is low.
[0004] In summary, the development of efficient enzyme-catalyzed methods for synthesizing adenosine and / or uridine is of great significance for the application fields of adenosine and uridine. Summary of the invention
[0005] In view of the deficiencies of the prior art and actual needs, the present invention provides a method for synthesizing adenosine and / or uridine by three-enzyme cascade catalysis. The present invention designs a process for synthesizing adenosine and / or uridine by three-enzyme cascade catalysis, and explores a specific enzyme combination to achieve efficient synthesis of adenosine and / or uridine.
[0006] To achieve the above object, the present invention adopts the following technical solutions:
[0007] In a first aspect, the present invention provides a method for synthesizing adenosine and / or uridine by three-enzyme cascade catalysis, the method comprising:
[0008] The method uses ribose compounds and nucleic acid bases as substrates, and uses ribokinase, pentose phosphate mutase and nucleoside phosphorylase as catalysts to react and synthesize adenosine and / or uridine. The ribose compounds include D-ribose and / or its derivatives, the nucleic acid bases include purine bases and / or pyrimidine bases, and the nucleoside phosphorylase includes purine nucleoside phosphorylase and / or pyrimidine nucleoside phosphorylase.
[0009] In the present invention, RK (ribokinase), PPM (phosphopentomutase) and NP (nucleoside phosphorylase) are integrated to construct a three-enzyme cascade method for synthesizing adenosine / uridine, and RK, PPM and NP are combined to achieve efficient synthesis of adenosine and / or uridine.
[0010] In the present invention, RK, PPM and NP are combined, and the enzymes and their sources are as follows: ribokinase (RK), respectively from Acanthamoeba castellanii (AcRK) and Escherichia coli (EcRK); phosphopentomutase (PPM), respectively from Escherichia coli (EcPPM), Bacillus cereus (BcPPM), Streptococcus mutans (SmPPM) and Thermotoga maritima (TmPPM); purine nucleoside phosphorylase (PNP), respectively from Deinococcus geothermalis (DgPNP), Parageobacillus thermoglucosidasius (PtPNP) and Geobacillus stearothermophilus (GsPNP); pyrimidine nucleoside phosphorylase (PNP), respectively from Deinococcus geothermalis (DgPNP), Parageobacillus thermoglucosidasius (PtPNP) and Geobacillus stearothermophilus (GsPNP); nucleosidephosphorylase, PyNP), from Parageobacillus thermoglucosidasius (PtPyNP), Geobacillus stearothermophilus (GsPyNP) and Brevibacillus borstelensis (BbPyNP), respectively.
[0011] Preferably, the combination of RK, PPM and NP includes: a combination of AcRK, TmPPM and GsPNP, a combination of EcRK, TmPPM and GsPNP, a combination of EcRK, EcPPM and GsPNP, a combination of EcRK, BcPPM and GsPNP, a combination of EcRK, SmPPM and GsPNP, a combination of EcRK, TmPPM and PtPNP, a combination of EcRK, TmPPM and DgPNP, a combination of EcRK, TmPPM and PtPyNP, a combination of EcRK, TmPPM and GsPyNP, a combination of EcRK, TmPPM and BbPyNP, a combination of EcRK, TmPPM and PtPyNP or a combination of EcRK, TmPPM and GsPyNP.
[0012] Preferably, the amino acid sequence of the ribokinase comprises the sequence shown in SEQ ID NO.1 (AcRK) or SEQ ID NO.2 (EcRK).
[0013] Preferably, the amino acid sequence of the pentose phosphate mutase includes the sequence shown in SEQ ID NO.3 (EcPPM), SEQ ID NO.4 (BcPPM), SEQ ID NO.5 (SmPPM) or SEQ ID NO.6 (TmPPM).
[0014] Preferably, the amino acid sequence of the purine nucleoside phosphorylase includes the sequence shown in SEQ ID NO.7 (DgPNP), SEQ ID NO.8 (PtPNP) or SEQ ID NO.9 (GsPNP).
[0015] Preferably, the amino acid sequence of the pyrimidine nucleoside phosphorylase comprises the sequence shown in SEQ ID NO.10 (PtPyNP), SEQ ID NO.11 (GsPyNP) or SEQ ID NO.12 (BbPyNP).
[0016] It can be understood that the specific RK, PPM and NP discovered in the present invention, the enzyme obtained by replacing, deleting or adding one or at least two amino acid residues to the enzyme, and the function is the same or similar to the original protein, can also be expected to achieve the effect of the present invention.
[0017] SEQ ID NO.1: AcRK
[0018] MEENQQQCPVRHIWEPQQGQVQQQASTGSECPVRNTWDTSSLYHTNGQFQHPPISQTNGQARCPMGYFSISASSGAPASSSDGAPKCPFASLSLGSSTDRRAPPEQLRLTILGHVTNDINIFVGKETRAQGGGVLFSGVAASNLGMNVEVVTKCSAEDKPVFQKIFAPSGTKVQFLPSQETTCCENNYPKPNSDERVQRFHAVGAPFTVDDLKHIESTIVHINPLSYGEFPDELIPKIKELNPSVQYLVADAQGFIRHIDMQNGGKISHKDWAAKEQYLKYFDLFKVDDKEATVLTGEKDMKRAMQILHEKGAKMVLGTYNAGVLLFDGNIFYQASFGPWKVEGRTGRGDTVTASFLAAAGLSGGPWKRNVALEFAARVTTTKMQYPGPYRRPTASL。
[0019] SEQ ID NO.2:EcRK
[0020] MQNAGSLVVLGSINADHILNLQSFPTPGETVTGNHYQVAFGGKGANQAVAAGRSGANIAFIACTGDDSIGESVRQQLATDNIDITPVSVIKGESTGVALIFVNGEGENVIGIHAGANAALSPALVEAQRERIANASALLMQLESPLESVMAAAKIAHQNKTIVALNPAPARELPDELLALVDIITPNETEAEKLTGIRVENDEDAAKAAQVLHEKGIRTVLITLGSRGVWASVNGEGQRVPGFRVQAVDTIAAGDTFNGALITALLEEKPLPEAIRFAHAAAAIAVTRKGAQPSVPWREEIDAFLDRQR。
[0021] SEQ ID NO.3:EcPPM
[0022] MKRAFIMVLDSFGIGATEDAERFGDVGADTLGHIAECAKGEADNGRPGLNPNLPNLTRLGLAKAHEGSTGFIPAGMDGNAEVIGAYAWAHEMSGKDSVSGHWEIAGVPVLFEWGYFSDHENSFPQELLDKLVERANLPGYLGNCRSSGTVILDQLGEEHMKTGKPIFYTSAASVFQIACHEETFGLDKLYELCEIAREELTNGGYNIGRVIARPFIGDKAGNFQRTGNRRDLAVEPPAPTVLQKLVDEKHGQVVSVGKIADIYANCGITKKVKATGLDALFDATIKEMKEAGDNTIVFTNFVDFDSSWGHRRDVAGYAAGLELFDRRLPELMSLLRDDILILTADHGCDPTWTGTDHTREHIPVLVYGPKVKPGSLGHRETFADIGQTLAKYFGTSDMEYGKAMF.
[0023] SEQ ID NO.4:BcPPM
[0024] MNKYKRIFLVVMDSVGIGEAPDAEQFGDLGSDTIGHIAEHMNGLQMPNMVKLGLGNIREMKGISVEKPLGYYTKMQEKSTGKDTMTGHWEIMGLYIDTPFQVFPEGFPKELLDELEECTGRKIIGNKPASGTEILDELGQEQMETGSLIVYTSADSVLQIAAHEEVVPLDELYKICKIARELTLDEKYMVGRVIAR PFVGEPGNFTRTPNRHDYALKPFGRTVMNELKDSDYDVIAIGKISDIYDGEGVTESLRTKSNMDGMDKLVDTLNMDFTGLSFLNLVDFDALFGHRRDPQGYGEALQEYDARLPEVFAKLKEDDLLLITADHGNDPIHPGTDHTREYVPLLAYSPSMKEGGQELPLRQTFADIGATVAENFGVKMPEYGTSFLNELKK。
[0025] SEQ ID NO.5:SmPPM
[0026] MSLSTFNRIHLVVLDSVGIGAAPDANNFSNAGVPDGASDTLGHISKTVGLNVPNMAKIGLGNIPRDTPLKTVPAENHPTGYVTKLEEVSLGKDTMTGHWEIMGLNITEPFDTWFNGFPEEIISKIEKFSGRKVIREANKPYSGTAVIDDFGPRQMETGELIIYTSADPVLQIAAHEDVIPLDELYRICEYARSITLERPALLGRIIARPYVGKPRNFTRTANRHDYALSPFAPTVLNKLADAGVSTYAVGKINDIFNGSGITNDMGHNKSNSHGVDTLIKTMGLSAFTKGFSFTNLVDFDALYGHRRNAHGYRDCLHEFDERLPEIIAAMKVDDLLITADHGNDPTYAGTDHTREYVPLLAYSPSFTGNGVLPVGHYADISATIADNFGVDTAMIGESFLDKLI.
[0027] SEQ ID NO.6:TmPPM
[0028] MRVVLIVLDSVGIGEMPDAHLYGDEGSNTIVNTAKAVSGLHLPNMAKLGLGNLDDIPGVEPVKPAEGIYGKMMEKSPGKDTTTGHWEIAGVILKKPFDLFPEGFPKELIEEFERRTGRKVIGNKPASGTEIIKELGPIHEKTGALIVYTSADSVFQIAAKKEIVPLEELYRYCEIARELLNEMGYKVARVIARPFTGEWPNYVRTPERKDFSLEPEGKTLLDVLTENGIPVYGVGKIADIFAGRGVTENYKTKDNNDGIDKTISLMKEKNHDCLIFTNLVDFDTKYGHRNDPVSYAKALEEFDARLPEIMHNLNEDDVLFITADHGCDPTTPSTDHSREMVPLLGYGGRLKKDVYVGIRETFADLGQTIADIFGVPPLENGTSFKNLIWE.
[0029] SEQ ID NO.7:DgPNP
[0030] MVARVPARPFASPPATLDRVSVHLNARPGEIAETVLLPGDPLRAQHIAETFENPVQHNSVRGMLGFTGTYRGVPVSVQGTGMGIASSMIYVNELIRDYGCQTLIRVGTAGSYQPDVHVRDLVLAQAACTDSNINNIRFGLRNFAPIADFELLLRAYQMARDRGFATHVGNILSSDTFYQDDPESYKLWAQYGVLAVEMEAAGLYTLAAKYGVRALTILTISDHLVTREETTAEERQTTFNGMIEVALDAALGLAVPSNSM.
[0031] SEQ ID NO.8:PtPNP
[0032] MSIHIEAKQQEIAEKILLPGDPLRAQYIAETFLEGATCYNVRVRGMLGFTGTYKGHRISVQGTGMGVPSISIYVNELIQSYHVQTLIRVGTCGAIQKDVNVRDVILAMSASTDSNMNRLTFRGRDYAPTANFALLRTAYEVGAEKGLPLKVGSVFTADMFYNDEPDWETWARYGVLAVEMETAALYTLAAKFGRKALSVLTVSDHILTGEETTAQERQTTFNDMIEVALETAIRVE.
[0033] SEQ ID NO.9:GsPNP
[0034] MSVHIGAKEHEIADKILLPGDPLRAKYIAETFLEGATCYNQVRGMLGFTGTYKGHRISVQGTGMGVPSISIYTELMQSYNVQTLIRVGTCGAIQKDVKVRDVILAMTSSTDSQMNRMTFGGIDYAPTANFDLLKTAYEIGKEKGLQLKVGSVFTADMFYNENAQFEKLARYGVLAVEMETTALYTLAAKFGRKALSVLTVSDHILTGEETTAEERQTTFNEMIVALETAIRQ。
[0035] SEQ ID NO.10:PtPyNP
[0036] MVDLIAKKRDGYELSKEEIDFIIRGYTNGDIPDYQMSAFAMAVFFRGMTEEETAALTMAMVRSGDVIDLSKIEGMKVDKHSTGGVGDTTTLVLGPLVASVGVPVAKMSGRGLGHTGGTIDKLESVPGFHVEIDNEQFIELVNKNKIAIIGQTGNLTPADKKLYALRDVTATVDSIPLIASMISKKIAAGADAIVLDVKTGAGAFMKDFAGAKRLATAMVEIGKRVGRKTMAVISDMSQPLGYAVGNALEVKEAIDTLKKGPEDLQELCLTLGSYMVYLAEKASSLEEARALLEASIREGKALETFKVFLSAQGGDASVVDDPTKLPQAKYRWELEAPEDGYVAEIVADEVGTAAMLLGAGRATKEATIDLSVGLVLHKKVGDAVKKGESLVTTIYSNTENIEEVKQKLAKSIRLSSIPVAKPTLIYETIS.
[0037] SEQ ID NO.11:GsPyNP
[0038] MRMVDLIEKKRDGHALTKEEIQFIIEGYTKGDIPDYQMSALAMAIFFRGMNEEETAELTMAVHSGDTIDLSRIEGIKVDKHSTGGVGDTTTLVLGPLVASVGVPVAKMSGRGLGHTGGTIDKLESVPGFHVEITNDEFIDLVNKNKIAVVGQSGNLTPADKKLYALRDVTATVNSIPLIASMISKKIAAGADAIVLDVKTGVGAFMKDLNDAKALAKAMVDIGNRVGRKTMAIISDMSQPLGYAIGNALEVKEAIDTLKEGPEDFQELCLVLGSHMVYLAEKASSLEEARHMLEKAMKDGSALQTFKTFLAAQGGDASVVDDPSKLPQAKYIIELEAKEDGYVSEIVADAVGTAAMWLGAGRATKESTIDLAVGLVLRKKVGDAVKKGESLVTTIYSNREQVDDVKQKLYENIRISATPVQAPTLIYDKIS.
[0039] SEQ ID NO.12:BbPyNP
[0040] MRMVDIIAKKRDGLELSSEEIQFLVSGYTDGSIPDYQMSAWAMAVLLRGMTPRETGDLTLAMAGSGEQLDLSSLKGIKVDKHSTGGVGDKTTLVVAPLVAAAGIPVAKM SGRGLGHSGGTIDKLESFAGFQVERTREQFLQQVREIGVSVIGQSGNLTPADKKLYALRDVTATVEAVPLIASSIMSKKIAAGADAILLDVKVGKGAFMKTLEQAETLA SAMAQIGTQVGRRTVAVISDMNQPLGFAVGNALEVKEAIDTLAGRGPKDLTELALAIGAHMLVLGELVADVEEGRKRLEEIMDSGKAVEKLAQMIEAQGGNKEDVYNPD RLPKASLTAEVKASQDGYISAIDAETVGHASVVLGAGRLTKEMPIDLAVGIVLAKKRGDQVRKGDVLATVHANDEILLKQAVEELKGAYTYDSESLIDQPLIYKIITE.
[0041] Preferably, the derivatives include aldopentose such as D-arabinose, L-arabinose, D-xylose, L-lyxose and D-ribose; deoxysugars such as 2'-deoxy-D-ribose, 2',3'-dideoxy-D-ribose, D-fucose, L-fucose, D-rhamnose, L-rhamnose and the like.
[0042] Preferably, the purine base comprises purine, adenine, guanine, 6-hydroxypurine, 6-fluoropurine, 6-chloropurine, 6-methylaminopurine, 6-dimethylaminopurine, 6-trifluoromethylaminopurine, 6-benzoylaminopurine, 6-acetylaminopurine, 6-hydroxyaminopurine, 6-methoxypurine, 6-benzoyloxypurine, 6-methylpurine, 6-ethylpurine, 6-trifluoromethylpurine, 6-phenylpurine, 6-mercaptopurine, 6-methylmercaptopurine, 2,6-diaminopurine, 2-amino-6-chloropurine, 2-amino-6-iodopurine, 2-aminopurine, 2-amino-6-mercaptopurine, 2-amino-6-methylmercaptopurine, 2-amino-6-hydroxyaminopurine, 2-amino-6-methoxypurine, 2-amino-6- Methylpurine, 2-amino-6-cyclopropylaminomethylpurine, 2-amino-6-phenylpurine, 2-amino-8-bromopurine, 6-cyanopurine, 2-chloroadenine, 2-fluoroadenine, 2-propylguanine, 2-aminopropyladenine, 3-deazaadenine, 3-deazaguanine, 9-methylhypoxanthine, xanthine, hypoxanthine, 6-methyladenine, 6-thioguanine, 7-methyladenine, 7-methylguanine, 7-deazaguanine, 7-deaza-8-azaguanine, 8-nitroadenine, 8-nitroguanine, 8-fluoroadenine, 8-chloroadenine, 8-bromoadenine, 8-aminoadenine, 8-hydroxyadenine, 8-fluoroguanine, 8-chloroguanine, 8-bromoguanine, 8-aminoguanine or 8-hydroxyguanine, etc.
[0043] Preferably, the pyrimidine bases include cytosine, uracil, 5-fluorocytosine, 5-fluorouracil, 5-chlorocytosine, 5-chlorouracil, 5-bromocytosine, 5-bromouracil, 5-iodocytosine, 5-iodouracil, 5-methylcytosine, 5-methyluracil, 5-ethylcytosine, 5-ethyluracil, 5-fluoromethylcytosine, 5-fluoromethyluracil, 5-trifluoromethylcytosine, 5-trifluoromethyluracil, 5-ethylene uracil, 5-bromovinyluracil, 5-chlorovinyluracil, 5-ethynylcytosine, 5-ethynyluracil, 5-propynyluracil, 5-hydroxycytosine, 5-methoxyuracil, 2-thiocytosine, 2-thiouracil, 2-thiothymine, 3-methylcytosine, 4-thiouracil, 4-thiothymine, 5,6-dihydrocytosine, 5-nitrocytosine, N4-ethylcytosine or N4-acetylcytosine, etc.
[0044] Preferably, the molar ratio of the ribose compound to the nucleic acid base is 1:(1.1-1.3).
[0045] Preferably, the addition ratio of the ribose compound, ribokinase, pentose phosphomutase and nucleic acid phosphorylase is 1:0.1:0.1:0.1.
[0046] Preferably, the reaction temperature is 30-40°C, including but not limited to 31°C, 32°C, 35°C, 36°C, 37°C, 38°C or 39°C, and the reaction time is 0.5-2h, including but not limited to 0.6h, 0.7h, 0.8h, 0.9h, 1h, 1.2h, 1.5h, 1.6h, 1.8h or 1.9h.
[0047] Compared with the prior art, the present invention has the following beneficial effects:
[0048] The present invention integrates RK (ribokinase), PPM (phosphopentomutase) and NP (nucleoside phosphorylase) to construct a three-enzyme hierarchical synthesis method of adenosine / uridine, and explores the combination of RK, PPM and NP to achieve efficient synthesis of adenosine and / or uridine. BRIEF DESCRIPTION OF THE DRAWINGS
[0049] Figure 1 This is the SDS-PAGE picture of enzyme purification;
[0050] Figure 2 This is the HPLC detection chart of adenosine synthesis;
[0051] Figure 3 This is the HPLC detection chart of 2-aminoadenosine synthesis;
[0052] Figure 4 This is the HPLC detection chart of 2-fluoroadenosine synthesis;
[0053] Figure 5 This is the HPLC detection chart of 2'-deoxyadenosine synthesis;
[0054] Figure 6 This is the HPLC detection chart of 2-amino-2'-deoxyadenosine synthesis;
[0055] Figure 7 This is the HPLC detection chart of uridine synthesis;
[0056] Figure 8 This is the HPLC detection chart of 5-fluorouridine synthesis;
[0057] Fig. 9 This is the HPLC detection chart of 2'-deoxyuridine synthesis;
[0058] Fig.10 This is the HPLC detection chart of 5-fluoro-2'-deoxyuridine synthesis. DETAILED DESCRIPTION
[0059] To further illustrate the technical means and effects of the present invention, the present invention is further described below in conjunction with the embodiments and drawings. It should be understood that the specific implementation methods described herein are only used to explain the present invention, rather than to limit the present invention.
[0060] If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased through regular channels.
[0061] The enzymes and their sources involved in the specific embodiments of the present invention are as follows:
[0062] Ribokinase (RK), from Acanthamoeba castellanii (named as AcRK) and Escherichia coli (named as EcRK);
[0063] phosphopentomutase (PPM), from Escherichia coli (enzyme named EcPPM), Bacillus cereus (enzyme named BcPPM), Streptococcus mutans (enzyme named SmPPM) and Thermotoga maritima (enzyme named TmPPM);
[0064] Purine nucleoside phosphorylase (PNP) from Deinococcus geothermalis (named as DgPNP), Parageobacillus thermoglucosidasius (named as PtPNP) and Geobacillus stearothermophilus (named as GsPNP);
[0065] Pyrimidine nucleoside phosphorylase (PyNP) is from Parageobacillus thermoglucosidasius (enzyme named PtPyNP), Geobacillus stearothermophilus (enzyme named GsPyNP) and Brevibacillus borstelensis (enzyme named BbPyNP).
[0066] Example 1
[0067] Synthesis, cloning, expression and purification of ribokinase (RK), pentosephosphomutase (PPM), purine nucleoside phosphorylase (PNP), and pyrimidine nucleoside phosphorylase (PyNP) genes
[0068] Recombinant plasmids (plasmid vector is pET-28a(+)) containing genes shown in sequences SEQ ID NO.13-24 (corresponding amino acid sequences are shown in SEQ ID NO.1-12) were synthesized respectively through the whole gene, and the recombinant plasmids were introduced into Escherichia coli BL21 (DE3) competent cells by chemical transformation to obtain the corresponding recombinant strains.
[0069] Each recombinant strain was cultured in 10 mL LB medium containing 50 μg / mL kanamycin at 37°C overnight with shaking, and the overnight culture was transferred to 100 mL LB medium containing 50 μg / mL kanamycin at a ratio of 1% and cultured at 37°C with shaking until OD 600 Reach between 0.6 and 0.8. Add IPTG (isopropyl-β-D-thiogalactoside) to the shake flask to a final concentration of 0.4 mM, induce at 25°C for 18 hours, collect the bacteria by centrifugation at 5000 rpm for 10 minutes, wash the bacteria once with buffer A (100 mMTris·HCl, 100 mM NaCl, 10% glycerol (pH 7.5)), resuspend the bacteria with 10 mL of buffer A after centrifugation, and perform ultrasonic treatment. The obtained cell homogenate solution is centrifuged at 10000 rpm for 30 minutes. After centrifugation, the supernatant is filtered with a 0.45 μm filter membrane. The filtered supernatant is purified by nickel ion affinity chromatography. The obtained protein solution is passed through a PD-10 desalting column to remove imidazole, and then concentrated to about 10 mg / mL through an ultrafiltration tube. The obtained enzyme solution is frozen in a -80°C refrigerator for use. The purified protein SDS-PAGE test results are as follows: Figure 1 As shown, it shows that the required enzymes were successfully prepared, lane 1: AcRK; lane 2: EcRK; lane 3: EcPPM; lane 4: BcPPM; lane 5: SmPPM; lane 6: TmPPM; lane 7: DgPNP; lane 8: PtPNP; lane 9: GsPNP; lane 10: PtPyNP; lane 11: GsPyNP; lane 12: BbPyNP.
[0070] SEQ ID NO.13: AcRK
[0071]
[0072] SEQ ID NO.14:EcRK
[0073] atgcagaacgctggttctctggttgttctgggttctatcaacgctgaccacatcctgaacctgcagtctttcccgaccccgggtgaaaccgttaccggtaaccactaccaggtagcgttcggtggtaaaggcgctaaccaggctgttgctgctggtcgttctggtgctaacatcgctttcatcgcttgcaccggtgacgactctatcggtgaatctgttcgtcagcagctggctaccgacaacatcgacatcaccccggtttctgttatcaaaggtgaatctaccggtgttgctctgatcttcgttaacggtgaaggtgaaaacgttatcggtatccacgctggtgctaacgctgctctgtctccggctctggttgaagctcagcgtgaacgtatcgctaacgcttctgctctgctgatgcagctggaatctccgctggaatctgttatggctgctgctaaaatcgctcaccagaacaaaaccatcgttgctctgaacccggctccggctcgtgaactgccggacgaactgctggctctggttgacatcatcaccccgaacgaaaccgaagctgaaaaactgaccggtatccgtgttgaaaacgacgaagacgctgctaaagctgctcaggttctgcacgaaaaaggtatccgtaccgttctgatcaccctgggttctcgtggtgtttgggcttctgttaacggtgaaggtcagcgtgttccgggtttccgtgttcaggctgttgacaccatcgctgctggtgacaccttcaacggtgctctgatcaccgctctgctggaagaaaaaccgctgccggaagcgataaggttcgctcacgctgcggctgctatcgctgttacccgtaaaggtgctcagccgtctgttccgtggcgtgaagaaatcgacgctttcctggaccgtcagcgt。
[0074] SEQ ID NO.15:EcPPM
[0075]
[0076] SEQ ID NO.16:BcPPM
[0077]
[0078] SEQ ID NO.17:SmPPM
[0079]
[0080] SEQ ID NO.18:TmPPM
[0081]
[0082] SEQ ID NO.19:DgPNP
[0083] atggttgctcgtgttccggctcgtccgttcgcttctccgccggctaccctggaccgtgtttctgttcacctgaacgctcgtccgggtgaaatcgctgaaaccgttctgctgccgggtgacccgctgcgtgctcagcacatcgctgaaaccttcttcgaaaacccggttcagcacaactctgttcgtggtatgctgggtttcaccggtacctaccgtggtgttccggtttctgttcagggtaccggtatgggtatcgcttcttctatgatctacgttaacgaactgatccgtgactacggttgccagaccctgatccgtgttggtaccgctggttcttaccagccggacgttcacgttcgtgacctggttctggctcaggctgcttgcaccgactctaacatcaacaacatccgtttcggtctgcgtaacttcgctccgatcgctgacttcgaactgctgctgcgtgcttaccagatggctcgtgaccgtggtttcgctacccacgttggtaacatcctgtcttctgacaccttctaccaggacgacccggaatcttacaaactgtgggctcagtacggtgttctggctgttgaaatggaagctgctggtctgtacaccctggctgctaaatacggtgttcgtgctctgaccatcctgaccatctctgaccacctggttacccgtgaagaaaccaccgctgaagaacgtcagaccaccttcaacggtatgatcgaagttgctctggacgctgctctgggtctggctgttccgtctaactctatgtaaggatcc。
[0084] SEQ ID NO.20:PtPNP
[0085] atgtctatccacatcgaagctaaacagcaggaaatcgctgaaaaaatcctgctgccgggtgacccgctgcgtgctcagtacatcgctgaaaccttcctggaaggtgctacctgctacaaccgtgttcgtggtatgctgggtttcaccggtacctacaaaggtcaccgtatctctgttcagggtaccggtatgggtgttccgtctatctctatctacgttaacgaactgatccagtcttaccacgttcagaccctgatccgtgttggtacctgcggtgctatccagaaagacgttaacgttcgtgacgttatcctggctatgtctgcttctaccgactctaacatgaaccgtctgaccttccgtggtcgtgactacgctccgaccgctaacttcgctctgctgcgtaccgcttacgaagttggtgctgaaaaaggtctgccgctgaaagttggttctgttttcaccgctgacatgttctacaacgacgaaccggactgggaaacctgggctcgttacggtgttctggctgttgaaatggaaaccgctgctctgtacaccctggctgctaaattcggtcgtaaagctctgtctgttctgaccgtttctgaccacatcctgaccggtgaagaaaccaccgctcaggaacgtcagaccaccttcaacgacatgatcgaagttgctctggaaaccgctatccgtgttgaataaggatcc。
[0086] SEQ ID NO.21:GsPNP
[0087] atgtctgttcacatcggtgctaaagaacacgaaatcgctgacaaaatcctgctgccgggtgacccgctgcgtgctaaatacatcgctgaaaccttcctggaaggtgctacctgctacaaccaggttcgtggtatgctgggtttcaccggtacctacaaaggtcaccgtatctctgttcagggtaccggtatgggtgttccgtctatctctatctacatcaccgaactgatgcagtcttacaacgttcagaccctgatccgtgttggtacctgcggtgctatccagaaagacgttaaagttcgtgacgttatcctggctatgacctcttctaccgactctcagatgaaccgtatgaccttcggtggtatcgactacgctccgaccgctaacttcgacctgctgaaaaccgcttacgaaatcggtaaagaaaaaggtctgcagctgaaagttggttctgttttcaccgctgacatgttctacaacgaaaacgctcagttcgaaaaactggctcgttacggtgttctggctgttgaaatggaaaccaccgctctgtacaccctggctgctaaattcggtcgtaaagctctgtctgttctgaccgtttctgaccacatcctgaccggtgaagaaaccaccgctgaagaacgtcagaccaccttcaacgaaatgatcgaagttgctctggaaaccgctatccgtcagtaaggatcc。
[0088] SEQ ID NO.22:PtPyNP
[0089]
[0090] SEQ ID NO.23:GsPyNP
[0091]
[0092] SEQ ID NO.24:BbPyNP
[0093]
[0094] Example 2
[0095] This example uses AcRK, TmPPM and GsPNP to synthesize adenosine in one pot.
[0096] 1 mL of a reaction solution consisting of 1 g / L 5 mM D-ribose (Adamas-beta, reagent grade), 1 g / L adenine hydrochloride (Adamas-beta, reagent grade), 5 mM 5'-adenine nucleotide disodium salt (Adamas-beta, reagent grade), 5 mM magnesium chloride (Adamas-beta, reagent grade), 0.1 mM manganese chloride (Adamas-beta, reagent grade), 0.1 g / L AcRK, 0.1 g / L TmPPM, 0.1 g / L GluPNP and 50 mM Tris-HCl buffer (pH 8.0) was reacted at 37°C for 1 h, and 0.1 mL of dilute hydrochloric acid (0.1 mol / L) was added to terminate the reaction. The HPLC analysis of the solution after the reaction was as follows: Figure 2 As shown, a is adenosine standard; b is a blank control without enzyme; c is a catalytic solution containing EcRK, TmPPM and GsPNP. After the reaction, there is a peak in the solution that is exactly the same as the peak of adenosine (Adamas-beta, reagent grade), indicating that adenosine was successfully prepared. Calculated by the area percentage method, the adenosine synthesis efficiency is 19.6%.
[0097] HPLC analysis conditions:
[0098] Column: Atlantis T3, 3um, 3.0*150mm;
[0099] Column temperature: 30°C;
[0100] Pump flow rate: 1.0 mL / min;
[0101] Detection: UV 250nm;
[0102] Mobile phase: Mobile phase A is acetonitrile (containing 0.05% formic acid), and mobile phase B is ultrapure water (containing 0.05% formic acid);
[0103] Elution program: 0-2min 100% B; 2-4min 0-30% A; 4-10min 30-90% A; 10-10.1min 90-0% A; 10.1-13min 100% B.
[0104] Example 3
[0105] This example uses EcRK, TmPPM and GsPNP to synthesize adenosine in one pot.
[0106] Compared with Example 2, the only difference is that an equal amount of EcRK is used instead of AcRK. After the reaction is completed, HPLC analysis as described in Example 2 is performed. The results show that there is a peak in the solution after the reaction that is completely identical to the peak of adenosine (Adamas-beta, reagent grade). Calculated by area percentage, the adenosine synthesis efficiency is 29.4%.
[0107] Example 4
[0108] This example uses EcRK, EcPPM and GsPNP to synthesize adenosine in one pot.
[0109] Compared with Example 2, the only difference is that an equal amount of EcRK is used to replace AcRK, and an equal amount of EcPPM is used to replace TmPPM. After the reaction is completed, HPLC analysis as described in Example 2 is performed, and the results show that there is a peak in the solution after the reaction that is completely identical to the peak of adenosine (Adamas-beta, reagent grade), and the adenosine synthesis efficiency is 28.4% calculated by area percentage.
[0110] Example 5
[0111] This example uses EcRK, BcPPM and GsPNP to synthesize adenosine in one pot.
[0112] Compared with Example 2, the only difference is that an equal amount of EcRK is used to replace AcRK, and an equal amount of BcPPM is used to replace TmPPM. After the reaction is completed, HPLC analysis as described in Example 2 is performed, and the results show that there is a peak in the solution after the reaction that is completely identical to the peak of adenosine (Adamas-beta, reagent grade), and the adenosine synthesis efficiency is 27.3% calculated by area percentage.
[0113] Example 6
[0114] This example uses EcRK, SmPPM and GsPNP to synthesize adenosine in one pot.
[0115] Compared with Example 2, the only difference is that an equal amount of EcRK is used to replace AcRK, and an equal amount of SmPPM is used to replace TmPPM. After the reaction is completed, HPLC analysis as described in Example 2 is performed, and the results show that there is a peak in the solution after the reaction that is completely identical to the peak of adenosine (Adamas-beta, reagent grade), and the adenosine synthesis efficiency is 31.3% calculated by area percentage.
[0116] Example 7
[0117] This example uses EcRK, TmPPM and DgPNP to synthesize adenosine in one pot.
[0118] Compared with Example 2, the only difference is that an equal amount of EcRK is used to replace AcRK, and an equal amount of DgPNP is used to replace GsPNP. After the reaction is completed, HPLC analysis as described in Example 2 is performed, and the results show that there is a peak in the solution after the reaction that is completely identical to the peak of adenosine (Adamas-beta, reagent grade), and the adenosine synthesis efficiency is 41.0% calculated by area percentage.
[0119] Example 8
[0120] This example uses EcRK, TmPPM and PtPNP to synthesize adenosine in one pot.
[0121] Compared with Example 2, the only difference is that an equal amount of EcRK is used to replace AcRK, and an equal amount of PtPNP is used to replace GsPNP. After the reaction is completed, HPLC analysis as described in Example 2 is performed, and the results show that there is a peak in the solution after the reaction that is completely identical to the peak of adenosine (Adamas-beta, reagent grade), and the adenosine synthesis efficiency is 42.2% calculated by area percentage.
[0122] Example 9
[0123] In this example, 2-aminoadenosine was synthesized by a one-pot method using EcRK, TmPPM and GsPNP.
[0124] Compared with Example 2, the only difference is that an equal amount of EcRK is used instead of AcRK, and an equal amount of 2-amino-adenine is used instead of adenine hydrochloride. After the reaction is completed, HPLC analysis as described in Example 2 is performed, and the results are as follows: Figure 3 As shown, a is a 2-aminoadenosine standard; b is a blank control without enzyme; c is a catalytic solution containing EcRK, TmPPM and GsPNP. After the reaction, there is a peak in the solution that is exactly the same as the peak of 2-aminoadenosine (Adamas-beta, reagent grade). Calculated by area percentage, the 2-aminoadenosine synthesis efficiency is 22.0%.
[0125] Example 10
[0126] In this example, 2-fluoroadenosine was synthesized by a one-pot method using EcRK, TmPPM and GsPNP.
[0127] Compared with Example 2, the only difference is that an equal amount of EcRK is used instead of AcRK, and an equal amount of 2-fluoroadenine is used instead of adenine hydrochloride. After the reaction is completed, HPLC analysis as described in Example 2 shows that there is a peak in the solution after the reaction that is completely identical to the peak of 2-fluoroadenosine (Adamas-beta, reagent grade) ( Figure 4 ), a is 2-fluoroadenosine standard; b is blank control without enzyme; c is catalytic solution containing EcRK, TmPPM and GsPNP. Calculated by area percentage, the 2-fluoroadenosine synthesis efficiency is 10.7%.
[0128] Embodiment 11
[0129] In this example, 2'-deoxyadenosine was synthesized by a one-pot method using EcRK, TmPPM and GsPNP.
[0130] Compared with Example 2, the only difference is that an equal amount of EcRK is used to replace AcRK, and an equal amount of 2'-deoxy-D-ribose is used to replace D-ribose. After the reaction is completed, HPLC analysis as described in Example 2 shows that there is a peak in the solution after the reaction that is completely identical to the peak of 2'-deoxyadenosine (Adamas-beta, reagent grade) ( Figure 5 ), a is 2'-deoxyadenosine standard; b is blank control without enzyme; c is catalytic solution containing EcRK, TmPPM and GsPNP. Calculated by area percentage, the 2'-deoxyadenosine synthesis efficiency is 25.6%.
[0131] Example 12
[0132] In this example, 2'-deoxyadenosine was synthesized by a one-pot method using EcRK, EcPPM and GsPNP.
[0133] Compared with Example 2, the only difference is that an equal amount of EcRK is used to replace AcRK, an equal amount of EcPPM is used to replace TmPPM, and an equal amount of 2'-deoxy-D-ribose is used to replace D-ribose. After the reaction is completed, HPLC analysis as described in Example 2 shows that there is a peak in the solution after the reaction that is completely identical to the peak of 2'-deoxyadenosine (Adamas-beta, reagent grade). Calculated by area percentage, the 2'-deoxyadenosine synthesis efficiency is 28.2%.
[0134] Example 13
[0135] In this example, 2'-deoxyadenosine was synthesized by a one-pot method using EcRK, BcPPM and GsPNP.
[0136] Compared with Example 2, the only difference is that an equal amount of EcRK is used to replace AcRK, an equal amount of BcPPM is used to replace TmPPM, and an equal amount of 2'-deoxy-D-ribose is used to replace D-ribose. After the reaction is completed, HPLC analysis as described in Example 2 shows a peak in the solution after the reaction that is completely identical to the peak of 2'-deoxyadenosine (Adamas-beta, reagent grade), and the 2'-deoxyadenosine synthesis efficiency is 26.3% calculated by area percentage.
[0137] Embodiment 14
[0138] In this example, EcRK, SmPPM and GsPNP were used to synthesize 2'-deoxyadenosine in one pot.
[0139] Compared with Example 2, the only difference is that an equal amount of EcRK is used to replace AcRK, an equal amount of SmPPM is used to replace TmPPM, and an equal amount of 2'-deoxy-D-ribose is used to replace D-ribose. After the reaction is completed, HPLC analysis as described in Example 2 shows a peak in the solution after the reaction that is completely identical to the peak of 2'-deoxyadenosine (Adamas-beta, reagent grade). Calculated by area percentage, the 2'-deoxyadenosine synthesis efficiency is 33.1%.
[0140] Embodiment 15
[0141] In this example, 2'-deoxyadenosine was synthesized by a one-pot method using EcRK, BcPPM and DgPNP.
[0142] Compared with Example 2, the only difference is that an equal amount of EcRK is used to replace AcRK, an equal amount of BcPPM is used to replace TmPPM, an equal amount of DgPNP is used to replace GsPNP, and an equal amount of 2'-deoxy-D-ribose is used to replace D-ribose. After the reaction is completed, HPLC analysis as described in Example 2 shows a peak in the solution after the reaction that is completely identical to the peak of 2'-deoxyadenosine (Adamas-beta, reagent grade). Calculated by area percentage, the 2'-deoxyadenosine synthesis efficiency is 33.1%.
[0143] Example 16
[0144] In this example, 2'-deoxyadenosine was synthesized by a one-pot method using EcRK, BcPPM and PtPNP.
[0145] Compared with Example 2, the only difference is that an equal amount of EcRK is used to replace AcRK, an equal amount of BcPPM is used to replace TmPPM, an equal amount of PtPNP is used to replace GsPNP, and an equal amount of 2'-deoxy-D-ribose is used to replace D-ribose. After the reaction is completed, HPLC analysis as described in Example 2 shows a peak in the solution after the reaction that is completely identical to the peak of 2'-deoxyadenosine (Adamas-beta, reagent grade). Calculated by area percentage, the 2'-deoxyadenosine synthesis efficiency is 32.5%.
[0146] Embodiment 17
[0147] In this example, 2-amino-2'-deoxyadenosine was synthesized by a one-pot method using EcRK, TmPPM and DgPNP.
[0148] Compared with Example 2, the only difference is that an equal amount of EcRK is used to replace AcRK, an equal amount of DgPNP is used to replace GsPNP, an equal amount of 2'-deoxy-D-ribose is used to replace D-ribose, and an equal amount of 2-aminoadenine is used to replace adenine hydrochloride. After the reaction is completed, HPLC analysis as described in Example 2 shows a peak in the solution after the reaction that is completely identical to the peak of 2-amino-2'-deoxyadenosine (Adamas-beta, reagent grade). Calculated by area percentage, the synthesis efficiency of 2-amino-2'-deoxyadenosine is 25.1%.
[0149] Embodiment 18
[0150] In this example, 2-amino-2'-deoxyadenosine was synthesized by a one-pot method using EcRK, TmPPM and PtPNP.
[0151] Compared with Example 2, the only difference is that an equal amount of EcRK is used to replace AcRK, an equal amount of PtPNP is used to replace GsPNP, an equal amount of 2'-deoxy-D-ribose is used to replace D-ribose, and an equal amount of 2-aminoadenine is used to replace adenine hydrochloride. After the reaction is completed, HPLC analysis as described in Example 2 shows a peak in the solution after the reaction that is completely identical to the peak of 2-amino-2'-deoxyadenosine (Adamas-beta, reagent grade). Calculated by area percentage, the synthesis efficiency of 2-amino-2'-deoxyadenosine is 24.4%.
[0152] Embodiment 19
[0153] In this example, 2-amino-2'-deoxyadenosine was synthesized by a one-pot method using EcRK, TmPPM and GsPNP.
[0154] Compared with Example 2, the only difference is that an equal amount of EcRK is used to replace AcRK, an equal amount of 2'-deoxy-D-ribose is used to replace D-ribose, and an equal amount of 2-aminoadenine is used to replace adenine hydrochloride. After the reaction is completed, HPLC analysis as described in Example 2 shows that there is a peak in the solution after the reaction that is completely identical to the peak of 2-amino-2'-deoxyadenosine (Adamas-beta, reagent grade) ( Figure 6 ), a is 2-amino-2'-deoxyadenosine standard; b is a blank control without enzyme; c is a catalytic solution containing EcRK, TmPPM and GsPNP. Calculated by area percentage, the 2-amino-2'-deoxyadenosine synthesis efficiency is 23.7%.
[0155] Embodiment 20
[0156] In this example, uridine was synthesized by a one-pot method using EcRK, TmPPM and PtPyNP.
[0157] 1 mL of a reaction solution consisting of 1 g / L D-ribose (Adamas-beta, reagent grade), 1 g / L uracil (Adamas-beta, reagent grade), 5 mM 5'-adenine nucleotide disodium salt (Adamas-beta, reagent grade), 5 mM magnesium chloride (Adamas-beta, reagent grade), 0.1 mM manganese chloride (Adamas-beta, reagent grade), 0.1 g / L EcRK, 0.1 g / L TmPPM, 0.1 g / L PtPyNP and 50 mM Tris-HCl buffer (pH 8.0) was reacted at 37°C for 1 h, and 0.1 mL of dilute hydrochloric acid (0.1 mol / L) was added to terminate the reaction. After the reaction, HPLC analysis as described in Example 2 showed a peak in the solution after the reaction that was identical to the peak of uridine (Adamas-beta, reagent grade). Calculated by area percentage, the uridine synthesis efficiency was 12.5%.
[0158] Embodiment 21
[0159] In this example, uridine was synthesized by a one-pot method using EcRK, TmPPM and GsPyNP.
[0160] Compared with Example 20, the only difference is that an equal amount of GsPyNP is used instead of PtPyNP. After the reaction is completed, HPLC analysis as described in Example 2 shows a peak in the solution after the reaction that is exactly the same as the peak of uridine (Adamas-beta, reagent grade), a is a uridine standard; b is a blank control without enzyme; c is a catalytic solution containing EcRK, TmPPM and GsPyNP, and the uridine synthesis efficiency is 11.9% calculated by area percentage.
[0161] Embodiment 22
[0162] This example uses EcRK, TmPPM and BbPyNP to synthesize uridine in one pot.
[0163] Compared with Example 20, the only difference is that an equal amount of BbPyNP is used instead of PtPyNP. After the reaction is completed, HPLC analysis as described in Example 2 shows a peak in the solution after the reaction that is identical to the peak of uridine (Adamas-beta, reagent grade). Calculated by area percentage, the uridine synthesis efficiency is 12.1%.
[0164] Embodiment 23
[0165] In this example, 5-fluorouridine was synthesized by a one-pot method using EcRK, TmPPM and PtPyNP.
[0166] Compared with Example 20, the only difference is that uracil is replaced by an equal amount of 5-fluorouracil. After the reaction is completed, HPLC analysis as described in Example 2 shows a peak in the solution after the reaction that is exactly the same as the peak of 5-fluorouridine (Adamas-beta, reagent grade). Calculated by area percentage, the 5-fluorouridine synthesis efficiency is 9.5%.
[0167] Embodiment 24
[0168] This example uses EcRK, TmPPM and GsPyNP to synthesize 5-fluorouridine in one pot
[0169] Compared with Example 20, the only difference is that an equal amount of GsPyNP is used instead of PtPyNP, and 5-fluorouracil is used instead of uracil. After the reaction is completed, HPLC analysis as described in Example 2 shows a peak in the solution after the reaction that is exactly the same as the peak of 5-fluorouridine (Adamas-beta, reagent grade) ( Fig. 9 ), a is a 5-fluorouridine standard; b is a blank control without enzyme; c is a catalytic solution containing EcRK, TmPPM and GsPyNP. Calculated by area percentage, the 5-fluorouridine synthesis efficiency is 9.6%.
[0170] Embodiment 25
[0171] In this example, 5-fluorouridine was synthesized by a one-pot method using EcRK, TmPPM and BbPyNP.
[0172] Compared with Example 20, the only difference is that an equal amount of BbPyNP is used instead of PtPyNP, and 5-fluorouracil is used instead of uracil. After the reaction is completed, HPLC analysis as described in Example 2 shows a peak in the solution after the reaction that is exactly the same as the peak of 5-fluorouridine (Adamas-beta, reagent grade). Calculated by area percentage, the synthesis efficiency of 5-fluorouridine is 9.5%.
[0173] Embodiment 26
[0174] In this example, 2'-deoxyuridine was synthesized by a one-pot method using EcRK, TmPPM and PtPyNP.
[0175] Compared with Example 20, the only difference is that 2'-deoxy-D-ribose is used in an equal amount instead of D-ribose. After the reaction is completed, HPLC analysis as described in Example 2 shows a peak in the solution after the reaction that is completely identical to the peak of 2'-deoxyuridine (Adamas-beta, reagent grade). Calculated by area percentage, the 2'-deoxyuridine synthesis efficiency is 10.8%.
[0176] Embodiment 27
[0177] In this example, 2'-deoxyuridine was synthesized by a one-pot method using EcRK, TmPPM and GsPyNP.
[0178] Compared with Example 20, the only difference is that an equal amount of GsPyNP is used instead of PtPyNP, and 2'-deoxy-D-ribose is used instead of D-ribose. After the reaction is completed, HPLC analysis as described in Example 2 shows a peak in the solution after the reaction that is exactly the same as the peak of 2'-deoxyuridine (Adamas-beta, reagent grade) ( Fig.10 ), a is a 2'-deoxyuridine standard; b is a blank control without enzyme; c is a catalytic solution containing EcRK, TmPPM and GsPyNP. Calculated by area percentage, the 2'-deoxyuridine synthesis efficiency is 11.6%.
[0179] Embodiment 28
[0180] In this example, 2'-deoxyuridine was synthesized by a one-pot method using EcRK, TmPPM and BbPyNP.
[0181] Compared with Example 20, the only difference is that an equal amount of BbPyNP is used instead of PtPyNP, and 2'-deoxy-D-ribose is used instead of D-ribose. After the reaction is completed, HPLC analysis as described in Example 2 shows a peak in the solution after the reaction that is exactly the same as the peak of 2'-deoxyuridine (Adamas-beta, reagent grade). Calculated by area percentage, the 2'-deoxyuridine synthesis efficiency is 11.8%.
[0182] Embodiment 29
[0183] In this example, 5-fluoro-2'-deoxyuridine was synthesized by a one-pot method using EcRK, TmPPM and PtPyNP.
[0184] Compared with Example 20, the only difference is that an equal amount of 2'-deoxy-D-ribose is used instead of D-ribose, and 5-fluorouracil is used instead of uracil. After the reaction is completed, HPLC analysis as described in Example 2 shows a peak in the solution after the reaction that is completely identical to the peak of 5-fluoro-2'-deoxyuridine (Adamas-beta, reagent grade). Calculated by area percentage, the synthesis efficiency of 5-fluoro-2'-deoxyuridine is 13.0%.
[0185] Embodiment 30
[0186] In this example, 5-fluoro-2'-deoxyuridine was synthesized by a one-pot method using EcRK, TmPPM and GsPyNP.
[0187] Compared with Example 20, the only difference is that an equal amount of GsPyNP is used to replace PtPyNP, 2'-deoxy-D-ribose is used to replace D-ribose, and 5-fluorouracil is used to replace uracil. After the reaction is completed, HPLC analysis as described in Example 2 shows a peak in the solution after the reaction that is exactly the same as the peak of 5-fluoro-2'-deoxyuridine (Adamas-beta, reagent grade), a is a 5-fluoro-2'-deoxyuridine standard; b is a blank control without enzyme; c is a catalytic solution containing EcRK, TmPPM and GsPyNP. Calculated by area percentage, the synthesis efficiency of 5-fluoro-2'-deoxyuridine is 13.1%.
[0188] Embodiment 31
[0189] In this example, 5-fluoro-2'-deoxyuridine was synthesized by a one-pot method using EcRK, TmPPM and BbPyNP.
[0190] Compared with Example 20, the only difference is that an equal amount of BbPyNP is used instead of PtPyNP, 2'-deoxy-D-ribose is used instead of D-ribose, and 5-fluorouracil is used instead of uracil. After the reaction is completed, HPLC analysis as described in Example 2 shows a peak in the solution after the reaction that is exactly the same as the peak of 5-fluoro-2'-deoxyuridine (Adamas-beta, reagent grade). Calculated by area percentage, the synthesis efficiency of 5-fluoro-2'-deoxyuridine is 12.1%.
[0191] The statistical analysis results are shown in Table 1, indicating that the present invention can efficiently prepare adenosine and uridine and their corresponding derivatives by specifically exploring ribokinase, pentose phosphomutase, purine nucleoside phosphorylase and pyrimidine nucleoside phosphorylase and designing a specific combination.
[0192] Table 1
[0193]
[0194]
[0195]
[0196] In summary, the present invention integrates RK (ribokinase, Sugarkinase), PPM (phosphopentomutase, Phosphopentomutase), NP (nucleoside phosphorylase, Nucleoside phosphorylase) to construct a three-enzyme hierarchical synthesis of adenosine / uridine, and explores the combination of RK, PPM and NP to provide a new idea for the efficient synthesis of adenosine and / or uridine. According to the existing biochemical knowledge and enzymology knowledge, by increasing the amount of enzyme added, optimizing the feed ratio of the three enzymes and the feed ratio of the substrate, optimizing the reaction conditions (pH, temperature, divalent cation type) and other measures, the conversion rate of the substrate in the reaction route of the present invention can be greatly improved, and it can be expected to reach or exceed the substrate conversion rate of the existing route. Moreover, the nucleoside derivative products with diversified reaction routes of the present invention also have obvious advantages over the products of other single routes.
[0197] The applicant declares that the present invention illustrates the detailed method of the present invention through the above-mentioned embodiments, but the present invention is not limited to the above-mentioned detailed method, that is, it does not mean that the present invention must rely on the above-mentioned detailed method to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of various raw materials of the product of the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.
Claims
1. A method for synthesizing adenosine and / or uridine by three-enzyme cascade catalysis, characterized in that: The method comprises: Using ribose compounds and nucleic acid bases as substrates, and using ribokinase, pentose phosphate mutase and nucleoside phosphorylase as catalysts, the reaction is carried out to synthesize adenosine and / or uridine; The ribose compound includes D-ribose and / or its derivatives; The nucleic acid bases include purine bases and / or pyrimidine bases; The nucleoside phosphorylase includes purine nucleoside phosphorylase and / or pyrimidine nucleoside phosphorylase.
2. The method for synthesizing adenosine and / or uridine by three-enzyme cascade catalysis according to claim 1, characterized in that: The amino acid sequence of the ribokinase includes the sequence shown in SEQ ID NO.1 or SEQ ID NO.
2.
3. The method for synthesizing adenosine and / or uridine by three-enzyme cascade catalysis according to claim 1 or 2, characterized in that: The amino acid sequence of the pentose phosphate mutase includes the sequence shown in SEQ ID NO.3, SEQ ID NO.4, SEQ ID NO.5 or SEQ ID NO.
6.
4. The method for synthesizing adenosine and / or uridine by three-enzyme cascade catalysis according to any one of claims 1 to 3, characterized in that: The amino acid sequence of the purine nucleoside phosphorylase includes the sequence shown in SEQ ID NO.7, SEQ ID NO.8 or SEQ ID NO.
9.
5. The method for synthesizing adenosine and / or uridine by three-enzyme cascade catalysis according to any one of claims 1 to 4, characterized in that: The amino acid sequence of the pyrimidine nucleoside phosphorylase includes the sequence shown in SEQ ID NO.10, SEQ ID NO.11 or SEQ ID NO.
12.
6. The method for synthesizing adenosine and / or uridine by three-enzyme cascade catalysis according to any one of claims 1 to 5, characterized in that: The derivatives include aldopentose and deoxysugars; Preferably, the aldopentose includes any one of D-arabinose, L-arabinose, D-xylose, L-lyxose or D-ribose; Preferably, the deoxy sugar includes any one of 2'-deoxy-D-ribose, 2',3'-dideoxy-D-ribose, D-fucose, L-fucose, D-rhamnose or L-rhamnose.
7. The method for synthesizing adenosine and / or uridine by three-enzyme cascade catalysis according to any one of claims 1 to 6, characterized in that: The purine bases include purine, adenine, guanine, 6-hydroxypurine, 6-fluoropurine, 6-chloropurine, 6-methylaminopurine, 6-dimethylaminopurine, 6-trifluoromethylaminopurine, 6-benzoylaminopurine, 6-acetylaminopurine, 6-hydroxyaminopurine, 6-methoxypurine, 6-benzoyloxypurine, 6-methylpurine, 6-ethylpurine, 6-trifluoromethylpurine, 6-phenylpurine, 6-mercaptopurine, 6-methylmercaptopurine, 2,6-diaminopurine, 2-amino-6-chloropurine, 2-amino-6-iodopurine, 2-aminopurine, 2-amino-6-mercaptopurine, 2-amino-6-methylmercaptopurine, 2-amino-6-hydroxyaminopurine, 2-amino-6-methoxypurine, 2-amino-6-methyl purine, 2-amino-6-cyclopropylaminomethylpurine, 2-amino-6-phenylpurine, 2-amino-8-bromopurine, 6-cyanopurine, 2-chloroadenine, 2-fluoroadenine, 2-propylguanine, 2-aminopropyladenine, 3-deazaadenine, 3-deazaguanine, 9-methylhypoxanthine, xanthine, hypoxanthine, 6-methyladenine, 6-thioguanine, 7-methyladenine, 7-methylguanine, 7-deazaguanine, 7-deaza-8-azaguanine, 8-nitroadenine, 8-nitroguanine, 8-fluoroadenine, 8-chloroadenine, 8-bromoadenine, 8-aminoadenine, 8-hydroxyadenine, 8-fluoroguanine, 8-chloroguanine, 8-bromoguanine, 8-aminoguanine or 8-hydroxyguanine.
8. The method for synthesizing adenosine and / or uridine by three-enzyme cascade catalysis according to any one of claims 1 to 7, characterized in that: The pyrimidine bases include cytosine, uracil, 5-fluorocytosine, 5-fluorouracil, 5-chlorocytosine, 5-chlorouracil, 5-bromocytosine, 5-bromouracil, 5-iodocytosine, 5-iodouracil, 5-methylcytosine, 5-methyluracil, 5-ethylcytosine, 5-ethyluracil, 5-fluoromethylcytosine, 5-fluoromethyluracil, 5-trifluoromethylcytosine, 5-trifluoromethyluracil, 5-vinyluracil, Cytosine, 5-bromovinyluracil, 5-chlorovinyluracil, 5-ethynylcytosine, 5-ethynyluracil, 5-propynyluracil, 5-hydroxycytosine, 5-methoxyuracil, 2-thiocytosine, 2-thiouracil, 2-thiothymine, 3-methylcytosine, 4-thiouracil, 4-thiothymine, 5,6-dihydrocytosine, 5-nitrocytosine, N4-ethylcytosine or N4-acetylcytosine.
9. The method for synthesizing adenosine and / or uridine by three-enzyme cascade catalysis according to any one of claims 1 to 8, characterized in that: The molar ratio of the ribose compound to the nucleic acid base is 1:(1.1-1.3); Preferably, the mass ratio of the ribose compound, ribokinase, pentose phosphomutase and nucleoside phosphorylase is 1:0.1:0.1:0.
1.
10. The method for synthesizing adenosine and / or uridine by three-enzyme cascade catalysis according to any one of claims 1 to 8, characterized in that: The reaction temperature is 30-40°C and the reaction time is 0.5-2h.
